By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting out of Aurora, Colorado, by NewsRx editors, research stated, "Progestins play a deleterious role in the onset of breast cancer, yet their influence on existing breast cancer and tumor progression is not well understood. In luminal estrogen receptor (ER)-and progesterone receptor (PR)-positive breast cancer, progestins induce a fraction of cells to express cytokeratin 5 (CK5), a marker of basal epithelial and progenitor cells in the normal breast."
Our news journalists obtained a quote from the research from the University of Colorado, "CK5(+) cells lose expression of ER and PR and are relatively quiescent, increasing their resistance to endocrine and chemotherapy compared to intratumoral CK5(-)ER(+)PR(+) cells. Characterization of live CK5(+) cells has been hampered by a lack of means for their direct isolation. Here, we describe optical (GFP) and bioluminescent (luciferase) reporter models to quantitate and isolate CK5(+) cells in luminal breast cancer cell lines utilizing the human KRT5 gene promoter and a viral vector approach. Using this system, we confirmed that the induction of GFP(+)/CK5(+) cells is specific to progestins, is dependent on PR, can be blocked by antiprogestins, and does not occur with other steroid hormones. Progestin-induced, fluorescence-activated cell sorting-isolated CK5(+) cells had lower ER and PR mRNA, were slower cycling, and were relatively more invasive and sphere forming than their CK5(-) counterparts in vitro. Repeated progestin treatment and selection of GFP(+) cells enriched for a persistent population of CK5(+) cells, suggesting that this transition can be semi-permanent."
According to the news editors, the research concluded: "These data support that in PR(+) breast cancers, progestins induce a subpopulation of CK5(+)ER(-)PR(-) cells with enhanced progenitor properties and have implications for treatment resistance and recurrence in luminal breast cancer."
For more information on this research see: Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Hormones & Cancer, 2013;4(1):36-49 (see also technology.html">Biotechnology).
Our news journalists report that additional information may be obtained by contacting S.D. Axlund, Dept. of Pathology, University of Colorado Denver, Anschutz Medical Center, Aurora, CO, United States. Additional authors for this research include B.H. Yoo, R.B. Rosen, J. Schaack, P. Kabos, D.V. Labarbera and C.A Sartorius.
Keywords for this news article include: Biotechnology, Drugs, Aurora, Colorado, Oncology, Treatment, Chemotherapy, Progesterone, United States, Cancer Gene Therapy, Corpus Luteum Hormones, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC